PROF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Profound Medical Corp (PROF) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong growth potential driven by its innovative technologies, upcoming clinical data presentation, and positive analyst sentiment. While financials show losses, the significant YoY revenue growth and improving net income indicate progress. The technical indicators and options sentiment also support a positive outlook.
The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 64.614, indicating no overbought or oversold conditions. The stock is trading near its pivot point (6.371), with resistance levels at 6.772 and 7.02, showing potential for upward movement.
Upcoming presentation of clinical CAPTAIN data, which is considered a major milestone in prostate cancer treatment.
Strong analyst sentiment with a Buy rating and a $12 price target, indicating significant upside potential.
Revenue growth of 43.13% YoY in Q4 2025, showcasing business expansion.
Gross margin decreased by 5.86% YoY, which could indicate cost pressures.
The stock has a 60% chance to decline slightly (-1.26%) in the next day, which may deter short-term gains.
In Q4 2025, Profound Medical's revenue increased by 43.13% YoY to $5,977,000, while net income improved by 65.25% YoY to -$8,175,000. EPS also improved by 42.11% YoY to -0.27. However, gross margin dropped by 5.86% YoY to 66.77%, reflecting some cost challenges.
Lake Street analyst Ben Haynor maintains a Buy rating with a $12 price target, emphasizing the importance of upcoming clinical data and undervaluation of the company.
